WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc. will be jointly presenting a thematic poster at the "Novel Therapeutics in Pulmonary Fibrosis" session at the 2011 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 18, 2011. The poster entitled Differing Effects of Ambrisentan and Bosentan on Pulmonary Fibrosis and Lung Mechanics Following Bleomycin Instillation will be presented by John Liles, PhD of Gilead Sciences, Inc. and Craig Plato, PhD, CEO of Plato BioPharma, Inc.
"Human Idiopathic Pulmonary Fibrosis has no known effective treatment, and a dramatically poor prognosis," said Dr. Plato. "The thematic research being presented at the 2011 ATS Conference provides insights into differential benefit of selective versus non-selective endothelin receptor antagonists in a robust preclinical model of this debilitating disease. Importantly, for the first time, clinically-relevant functional endpoints such as arterial blood gases, lung function, and pulmonary hemodynamics have been utilized, in part, to reveal the benefit of selective endothelin receptor antagonism."
"One of PBI's key strengths is to leverage and impart our years of experience, expertise, and technology for every study we conduct. This approach offers clients an advantage over a typical contract research organization or functional service provider relationship. We strive to be an integral partner with our clients, delivering cutting-edge, high-resolution disease modeling and methods as well as insightful solutions to preclinical drug discovery challenges," said Dr. Plato. "I believe our joint presentation with Gilead at this year's ATS shows our commitment to these goals and value-add for our clients."
Founded in 2009, Plato BioPharma, Inc is a leading preclinical contract research organization (CRO). The company offers expert drug discovery